Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 221

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Minimal ovarian stimulation for IVF: appraisal of potential benefits and drawbacks

Fauser, Bart C.J.M., Devroey, Paul, Yen, Sam S.C., Gosden, Roger, Crowley, William F., Baird, David T., Bouchard, Philippe · 1999 · Human Reproduction

Abstract

Shortly after the first pregnancy following in-vitro fertilization (IVF) was reported in a spontaneous cycle, evidence accumulated that overall pregnancy chances per IVF attempt increase significantly when more than one embryo is transferred. Subsequently, ovarian stimulation protocols have been developed which aim at the ongoing growth of several follicles in normo-ovulatory women to obtain multiple oocytes for fertilization in vitro and multiple embryos. The presence of many pre-ovulatory follicles allows for easier oocyte retrieval, and less effective IVF, embryo culture and implantation. Clearly, current ovarian stimulation protocols take many weeks, are extremely complex and expensive, and are not without danger. New procedures are frequently introduced without proper scientific evaluation (ISLAT working group, 1998) and current IVF strategies have been questioned (Edwards et al., 1996; Olivennes and Frydman, 1998). In 1995, the worldwide number of IVF cycles was ∼250 000 (de Mouzon and Lancaster, 1997). Overall birth rates have been reported at 6–25% per cycle. Problems related to stimulation include emotional stress, abdominal discomfort, risks of short-term complications and uncertainties regarding long-term health consequences for both the mother and children of multiple pregnancies. Some observations suggest that even singleton pregnancies resulting from IVF are more frequently complicated by bleeding, pre-eclampsia, diabetes or premature deliveries (Schenker and Ezra, 1994). Thus, the decision to undertake IVF treatment should not be considered lightly. Approximately 25% of patients refrain from a second attempt after a first unsuccessful IVF cycle (P.Devroey, unpublished observations), even where the costs are reimbursed by insurance companies. Ovarian hyperstimulation syndrome (OHSS) is a serious and potentially life-threatening complication of IVF characterized by enlarged ovaries, extravasation of fluid to the abdominal cavity resulting in ascites, hypovolaemia and haemoconcentration. Eventually, renal failure, thromboembolic complications and respiratory distress may occur. Severe forms of OHSS are associated with pregnancy, and related human chorionic gonadotrophin (HCG) production, which renders its management even more complex. The incidence of moderate OHSS is estimated to be ∼6% per cycle, with severe cases approaching 2% (Aboulghar et al., 1996; Elchalal and Schenken, 1997). This means an annual worldwide occurrence of at least 5000 cases of serious OHSS. Several patients are hospitalized every year in most major fertility centres. With careful monitoring of ovarian response, the risks of this serious complication can be reduced, but never brought to zero. The number of deaths resulting from OHSS is unknown, but with proper management the incidence should be low. The health risks of hyperstimulation are easily quantifiable, but discussion continues about the other potential long-term health consequences of ovarian stimulation, especially concerning any association between stimulation and ovarian cancer. Although the epidemiological studies on gonadotrophin therapy published so far remain inconclusive (Shoham, 1994; Bristow and Karlan, 1996), it should be realized that experimental hypergonadotrophism and knock-out animal studies have suggested a relationship between long-term exposure to high gonadotrophin concentrations and the development of gonadal stromal tumours (Risma et al., 1995; Kumar et al., 1996; Kananen et al., 1997). Although the situation in women has not yet been clarified, the risk of ovarian cancer is probably very low, if it exists. It should be realized that negative results are not usually published and that many previous reports were retrospective and poorly controlled. However, the reduced risk of ovarian cancer observed in steroid contraceptive pill users suggests a link between ovarian tumours and gonadotrophins (or ovulation). It is also too early to exclude the possibility of risks, such as an earlier menopause due to increased follicular expenditure, although this seems highly unlikely because of the limited effects of follicle stimulating hormone (FSH) on a few follicles out of the thousands undergoing atresia. No evidence was obtained in studies on mice undergoing chronic treatment with pregnant mare's serum gonadotrophin (R.Gosden, unpublished observations). Finally, some studies have suggested that profound ovarian stimulation impairs endometrial receptivity and subsequent rates of embryo implantation (Simón et al., 1998). Over the years, the medication used for ovarian stimulation in IVF has included clomiphene citrate (CC), human menopausal gonadotrophin (HMG), and urinary FSH. Although still under investigation, it is increasingly clear that the overall IVF outcome has not improved significantly with the use of the recently introduced recombinant FSH preparations. Exogenous gonadotrophins are administered to stimulate multiple follicle development, usu

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/humrep/14.11.2681

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 221

Metadata

Authors
Fauser, B. C. J. M., Devroey, P., Yen, S. S. C., Gosden, R., Crowley, W. F., Baird, D. T., & Bouchard, P.
Venue
Human Reproduction
Published
1999-11-01
Volume
14
Issue
11
Pages
2681-2686
ISSN
  • 0268-1161 (ISSN-L)
  • 1460-2350
OpenAlex
W2113739954
Cited by
221
References
1
FWCI
12.94
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Minimal ovarian stimulation for IVF: appraisal of potential benefits and drawbacks. https://app.cochat.ai/papers/10.1093/humrep/14.11.2681
The paper
Fauser, B. C. J. M., Devroey, P., Yen, S. S. C., Gosden, R., Crowley, W. F., Baird, D. T., & Bouchard, P. (1999). Minimal ovarian stimulation for IVF: appraisal of potential benefits and drawbacks. Human Reproduction. https://doi.org/10.1093/humrep/14.11.2681

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.